Why Neurxstem
Neurxstem delivers regulator-aligned human molecular evidence with a level of precision not achievable in proxy systems.
The platform is the only patented human brain model producing reproducible, federally validated datasets already aligned with the FDA Modernization Act. With a decade-long head start and a peer-reviewed foundation, Neurxstem provides a defensible basis for diagnostics, therapeutics, aging research, and next-generation AI.
Evidence Base
98–99% reproducibility across lines
Direct human concordance (p < 10⁻¹⁰⁰)
IND-supportive multi-omic datasets
A decade of peer-reviewed and federally funded validation
The Sully Family Office Trust has committed significant financial support to advance this work, strengthening the continuity and long-term vision of Neurxstem’s scientific program.
A Decade-Long Head Start
Neurxstem began building human-derived models in 2015—eight years before the FDA made human evidence the regulatory standard for drug submissions.
Today, every therapeutic developer must access human-relevant data; Neurxstem is the only company with validated models, a patent, and NIH/DoD-funded datasets already in place.
Regulator-Aligned Platform
Our data meets the rigor required for IND-enabling studies, offering:
Direct human concordance at molecular scale
High-precision multi-omic readouts
Evidence designed for FDA and EMA pathways
60% attrition reduction and months saved in approval timelines
Strategic Positioning
Neurxstem sits at the intersection of human biology, regulatory-aligned evidence generation, and advanced AI health systems.
Our platform supports multiple verticals—diagnostics, therapeutics, aging, and molecular AI—while remaining grounded in a single validated biological engine. This structure ensures optionality without dilution, enabling long-term defensibility, scientific rigor, and category-defining product development.
Partnership Opportunities
Neurxstem enables collaborations across clinical research, diagnostics, aging, neurodegeneration, and AI health.
The platform supports IND-enabling data generation, mechanism-of-disease research, therapeutic development, and next-generation AI models built on molecular evidence. Opportunities include data partnerships, co-development programs, strategic investment, and integrations with early diagnostic and AI health systems.